Aslaner Ak, M. Et Al. 2023. The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.. Turkish journal of haematology : official journal of Turkish Society of Haematology , vol.40 , 92-100.

Aslaner Ak, M., Gedük, A., Acar, İ. H., Polat, M. G., Sunu, C., Bolaman, A. Z., ... Hacıbekiroğlu, T.(2023). The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.. Turkish journal of haematology : official journal of Turkish Society of Haematology , vol.40, 92-100.

Aslaner Ak, Müzeyyen Et Al. "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.," Turkish journal of haematology : official journal of Turkish Society of Haematology , vol.40, 92-100, 2023

Aslaner Ak, Müzeyyen A. Et Al. "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.." Turkish journal of haematology : official journal of Turkish Society of Haematology , vol.40, pp.92-100, 2023

Aslaner Ak, M. Et Al. (2023) . "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.." Turkish journal of haematology : official journal of Turkish Society of Haematology , vol.40, pp.92-100.

@article{article, author={Müzeyyen Aslaner Ak Et Al. }, title={The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.}, journal={Turkish journal of haematology : official journal of Turkish Society of Haematology}, year=2023, pages={92-100} }